Obstructive sleep apnea (OSA) is defined by frequent episodes of reduced or complete 39 cessation of airflow during sleep and is linked to negative health outcomes. Understanding the 40 genetic factors influencing expression of OSA may lead to new treatment strategies. Electronic 41 health records can be leveraged to both validate previously reported OSA-associated genomic 42 variation and detect novel relationships between these variants and comorbidities. We identified 43 candidate single nucleotide polymorphisms (SNPs) via systematic literature review of existing 44 research. Using datasets available at Geisinger (n=39,407) and Vanderbilt University Medical 45
INTRODUCTION 61
apnea[Title/Abstract] OR obstructive sleep apnoea[Title/Abstract])) AND (polymorphism OR 112 genetic variant OR genetic association OR gene OR genome wide association study OR 113 genome-wide association study). PubMed results were filtered to only include studies conducted 114 in humans (i.e. adults and children reflecting all ancestral backgrounds) and manuscripts written 115 in English. Manuscripts were excluded if there was evidence of being retracted. Abstracts were 116 manually reviewed to ensure that the results related to genetic studies conducted in humans 117 that were specifically relevant to OSA as opposed to phenotypes that may reflect something 118 other than an OSA diagnosis (e.g., intermittent hypoxia, sleep-disordered breathing, treatment 119 response, obesity). Studies were further excluded if there were no full-texts available, or 120 represented analyses of larger genomic regions for which individual variants could not be 121 identified (e.g., linkage analysis). The remaining eligible full manuscripts were manually 122 reviewed to identify candidate variants with evidence for association with OSA. Candidate 123 variants were then mapped to rsIDs and independent SNPs (r 2 <0.50) were selected using 124 genome-wide data (described in more detail below) from individuals in the Geisinger dataset. 125 Array (MEGA). Quality control (QC) procedures required DNA samples to have >90% 138 genotyping call rate and be unrelated based on PI-HAT≤0.05. Directly genotyped markers were 139 required to have >99% call rate with minor allele frequency >0.01, and p-values testing 140 significant deviation from Hardy-Weinberg Equilibrium >1x10 -7 . Genetically informed ancestry 141 was then determined using principal components analysis with reference human genomes 142 available via the 1000 Genomes Project, phase III 53 . The QCd genotype data for the European 143 ancestral dataset from Geisinger were imputed using Impute2 software and reference human 144 haplotypes available via the Haplotype Reference Consortium 54 . The QCd genotype data for the 145 European and African VUMC ancestral datasets were imputed using Impute2 and reference 146 human haplotypes available via the 1000 Genomes Project, phase III 53 . Imputed genotypes 147 were required to have info scores ≥0.3. Notably, while all other QC thresholds were required for 148 inclusion in association tests, given the goal to specifically evaluate previously reported OSA 149
candidate SNPs for associations with EHR-derived OSA status, some imputed SNPs with >1% 150 missingness in the VUMC datasets were tested for associations with an OSA diagnosis. 151
Specifically, there were six imputed SNPs that were missing in >1% of the VUMC European 152 ancestral dataset: rs1801278 (missing=22.7%), rs1799983 (missing=15.2%), rs1054135 153 (missing=41.8%), rs9526240 (missing=24.6%), rs9932581 (missing=79.7%), rs2743173 154 (missing=15.9%). In addition, there were five imputed SNPs that were missing in >1% of the 155 VUMC African ancestral dataset: (rs999944 (missing=19.3%), rs1801278 (missing=14.1%), 156 rs7804372 (missing=10.5%), rs9526240 (missing=10.9%), rs2743173 (missing=16.0%)). 157 158
Validation of previously reported OSA-associated genomic variants using diagnoses in 159
electronic health records 160 EHR-derived OSA cases (EHR-OSA) and non-cases (NonOSA) were defined using an 161 algorithm based on the total instances of International Classification of Diseases 9 th (ICD-9) or 162 10 th (ICD-10) revision OSA-related diagnostic codes (Table S1 ). This algorithm was validated 163 with clinical chart reviews at Geisinger and VUMC 55 . Based on the EHR algorithm validation 164 study, EHR-derived OSA was defined at each site using the minimum number of code instances 165 that achieved positive predictive value (PPV) and negative predictive value (NPV) of at least 166 90%. For the Geisinger dataset, EHR-OSA was defined as individuals with any OSA-related 167 codes present on at least three different dates in the EHR (PPV [95% CI] =94.9 [88.5, 98.3]; from VUMC with other genetically informed ancestries were too small to evaluate (total n=328 180 across all populations; data not shown), and therefore were excluded from this study. 181
The associations between SNPs previously implicated in OSA, that were selected during 182 literature reviews, and the validated EHR-derived diagnosis of OSA were evaluated using 183 logistic regression models, adjusting for age, sex and body mass index (BMI). For individuals 184 with EHR-OSA, age and BMI measures reflected those at the time of the first usage of an OSA 185 code, for individuals with no evidence of OSA the most recent age and BMI measures were 186 included in analyses. SNPs were coded additively with respect to the minor allele (0, 1 or 2 187 copies). As the purpose of this study was to validate individual candidate SNPs, each with a 188 priori evidence of effect, our significance was set at an uncorrected p<5.0×10 -2 . Results from 189 EHR-OSA association tests across the three datasets were then meta-analyzed using fixed-190 effects inverse-variance weighted meta-analyses in the METAL software package 57 . The 191 possibility of heterogeneity among the studies was also tested using METAL. 192 To determine if age, sex or BMI modified the associations between any candidate SNP 193 and EHR-OSA, we performed statistical interaction tests by including a product term (SNP x 194 Covariate) in the logistic models along with main effect terms. If this product term was significant 195 (p<5.0×10 -2 ), we tested the associations between OSA candidate SNPs and EHR-OSA 196 separately in subgroups stratified by the covariate of interest, adjusted for age, BMI and sex 197 (except when performing analyses in males/females separately). Age groups were defined as 198 ≤50 years and >50 years, based on evidence that prevalence of OSA increases substantially 199 above the age of 50 years-old 2 . BMI groups were stratified as ≤30 kg/m 2 and BMI>30 kg/m 2 , 200 based on accepted US standards of distinguishing normal-overweight from obese 58 . 201
202

Tests for associations between previously reported OSA candidate variants and 203 quantitative traits obtained from sleep study reports at Geisinger 204
Sleep reports linked with genome-wide data were available for a subset of the analysis 205 dataset from Geisinger (nNonOSA=1,614, nEHR-OSA=4,957); these data were not available for the 206 VUMC datasets. Linear regression models were used to test for additive effects of the minor 207 allele at OSA candidate SNPs and 12 quantitative traits pulled from sleep study (i.e. 208 polysomnography [PSG]) reports included in the EHR, adjusting for age, sex and BMI (defined 209 based on EHR-OSA status as described above in the EHR, variables were pulled from the most recent sleep study performed. For the majority 219 of the quantitative sleep report traits, the distributions did not meet the assumptions of normality 220 necessary for regression analyses. Prior to analyses, Box-Cox power transformations were 221 applied to sleep study variables and then Z-scores were calculated. For variables that had zero 222 values, half of the minimum non-zero value was added to each observation. 223
224
Phenome-wide association tests for previously reported OSA candidate variants and 225 other EHR-derived clinical traits: discovery (Geisinger) and replication (VUMC) 226
Logistic regression models were used to test for associations between the previously 227 reported OSA-associated SNPs and other non-OSA clinical codes, while adjusting for age, sex 228 and BMI (defined based on EHR-OSA status as described above). For discovery analyses, only 229 those codes resulting in a minimum sample size of 200 cases in the Geisinger dataset were 230 included. For each code being tested, 'cases' were defined as individuals with codes used on ≥3 231 different dates in the EHR and 'controls' were defined as individuals with absence of this code 232 or a code within the same hierarchy. Individuals with one or two instances of a code were 233 excluded from the association analysis for that code. Linear regression models were used to 234 test for associations between OSA candidate SNPs and clinical laboratory values. For discovery 235 analyses, only laboratory values available for ≥1,000 individuals in the Geisinger dataset were 236 included. In total, OSA candidate SNPs were tested for associations with 577 non-OSA ICD 237 codes and 143 different quantitative traits defined using Logical Observation Identifier Names 238 and Codes (LOINC) mapped median clinical laboratory values. Box-Cox power transformations 239 were applied for normality following inspection of the laboratory value distributions. 240
Codes and laboratory values that were associated with any candidate SNP based on a 241 false discovery rate multiple testing correction threshold (q<5.0×10 -2 ) were tested for replication 242 in the VUMC European ancestral dataset and generalization in the VUMC African ancestral 243 dataset. The significance threshold for replication and generalization was set at an uncorrected 244 p<5.0×10 -2 . To help circumvent issues related to potential differences in specific ICD code 245 usage across the two clinical sites, all ICD codes that reflected the same phenotype code 246 (PheCode) as the discovery ICD code, present on ≥3 different dates in the individual's record, 247
were tested for replication in the VUMC datasets. PheCodes are aggregations of one or more 248 related ICD code into distinct diseases or traits 60 . Prior to PheCode mapping, all ICD-10 codes 249 were mapped to the corresponding ICD-9 code using CMS General Equivalency Mapping 
Literature-derived identification of OSA candidate variants 260
A systematic literature review of 204 studies revealed 53 unique SNPs reported to be 261 associated with OSA and/or OSA severity ( Figure S1 ). Of the 53 SNPs, we were able to 262 evaluate associations with 48 variants: 46 were directly assessed, proxy SNPs were identified 263 for two (literature-derived SNP: rs35424364, proxy SNP: rs7752028, r 2 =0.97; literature-derived 264 SNP: rs25531, proxy SNP: rs11080123, r 2 =0.50), and five SNPs were dropped due to low allele 265 frequencies (MAF<0.01). Details for the 48 selected candidate SNPs, including the reported 266 effects and hyperlinks to the literature sources, are provided in Table S2 . As discussed above, 267 analyses were performed to validate these literature-reported associations in three independent 268 datasets representing clinical samples from two different US-based sites: Geisinger (European 269 American) and VUMC (European American and African American). 270
271
Sample Characteristics 272
Among the Geisinger sample of European ancestry, the mean age was 59 years (range 273 19-88 years), 41% of participants were male, the mean BMI was 31.61 kg/m 2 (range: 14.17-274 89.06, kg/m 2 ), and 14.6% of individuals met the EHR criteria for OSA. Individuals with EHR-275 defined OSA were older, had higher BMIs and were more likely to be male than non-OSA 276 participants ( Table 1 ). Among the VUMC European ancestry sample, the mean age was 57 277 years (range: 18-88 years), 42.4% were male and the mean BMI was 28.80 kg/m 2 (range: 278 10.71-93.65 kg/m 2 ). A total of 13.7% of individuals met the criteria for EHR-defined OSA, and 279 OSA participants were younger, had higher BMIs and were more likely to be male (Table 1) . 280
Among the VUMC African ancestral sample, the mean age was 47 years (range: 18-88 years), 281 37.8% were male and the mean BMI was 31.00 kg/m 2 (range: 10.59-78.73 kg/m 2 ). OSA was 282 defined using EHR-criteria in 9.7% of individuals. These individuals had higher BMIs compared 283 to EHR-defined NonOSA; however, age and sex were not significantly different at p<5.0×10 -2 284 (Table 1) . 285 286
Associations of OSA candidate variants with EHR-derived OSA 287
Eleven of the 48 OSA candidate SNPs tested were associated with an EHR-derived 288 diagnosis of OSA in at least on dataset (Tables 2 & S2, Figure 1 ). Specifically, five candidate 289
SNPs were associated with EHR-OSA in individuals of European ancestry in the Geisinger 290 dataset. These included two missense variants (rs1137100, β=-0.08, p=3.58×10 -3 ; and 291 rs1137101, β=-0.05, p=3.78×10 -2 ) in the leptin receptor (LEPR) gene, intronic variants in the 292 lysophosphatidic acid receptor 1 (LPAR1) gene (rs7030789, β=0.05, p=3.57×10 -2 ) and the 293 bleomycin hydrolase (BLMH) gene (rs11080123, β=0.13, p=2.18×10 -2 ; proxy SNP for the Solute 294
Carrier Family 6 Member 4 [SLC6A4] gene promoter variant (rs25531), and a variant ~2kb 295
upstream of the matrix metallopeptidase 9 (MMP9) gene (rs3918242; β=0.07, p=2.65×10 -2 ). 296
Three additional OSA candidate SNPs were associated with EHR-OSA in individuals with 297
European ancestry in the VUMC dataset. These included a missense variant located in the combined results across all three datasets indicated that there was one OSA candidate SNP, a 307 synonymous variant in the gamma-aminobutyric acid type B receptor subunit 1 (GABBR1) gene, 308 that was associated with EHR-OSA among all of the samples (rs29230; β=-0.05, p=2.27×10 -2 , 309
Effects of Age, Sex and BMI on Associations of OSA candidate variants with EHR-OSA 312
The associations between 15 OSA candidate SNPs and EHR-OSA were modified by at 313 least one OSA-related risk factor (i.e., age, sex, and/or BMI) evaluated in interaction tests 314 (Table S3 ). Interaction tests conducted in the Geisinger dataset indicated that age, sex or BMI 315 modified the associations between seven SNPs and EHR-OSA. However, only one SNP was 316 associated (p<5.0×10 -2 ) with EHR-OSA in stratified analyses ( Figure S2 , Table S3 ). Specifically, 317 age had an effect on the association between an intronic variant in the PPARG coactivator 1 318 beta (PPARGC1B) gene and EHR-OSA (rs6888451; Interaction β=-0.01, p=6.22×10 -3 ). No 319 differences were observed in subgroups stratified by clinically relevant values of age (≤50 years 320 [p=6.64x10 -1 ] vs. >50 years [p=8.48x10 -1 ] years). Similarly, while there was evidence of 321 differential effects in males and females for three SNPs: rs251864 (β=0.21, p=2.68×10 -2 ), 322 rs1800872 (β=-0.10, p=3.98×10 -2 ) and rs1409986 (β=-0.18, p=9.67×10 -3 ), no significant 323 associations were observed with EHR-OSA when examining associations separately in males 324 or females (Table S3 ). Finally, BMI had an effect on the associations between three SNPs and 325 EHR-OSA: rs1130864 (β=0.01, p=4.48×10 -2 ), rs1800629 (β=0.01, p=5.20×10 -3 ) and rs7804372 326 (β=0.01, p=4.11×10 -2 ). Analyses conducted separately in normal/overweight (BMI≤30 kg/m 2 ) 327 and obese (BMI>30 kg/m 2 ) participants indicated that the rs1800629 variant upstream of TNF-α 328 was associated with EHR-OSA primarily in individuals with BMI≤30 (β=-0.20, p=1.03×10 -2 ) 329 rather than those with BMI>30 (β=-0.01, p=7.69×10 -1 ). 330
In the VUMC European American dataset, age, sex or BMI modified the relationship 331 between eight SNPs and EHR-OSA (Table S3 ). Of these, two SNPs were associated 332 (p<5.0×10 -2 ) with EHR-OSA in covariate-defined subgroups ( Figure S2 , Table S3 ). Age modified 333 the association between a missense variant in the peroxisome proliferator activated receptor 334 gamma (PPARG) gene and EHR-OSA (rs1801282; β=0.01, p=6.64×10 -3 ). The association 335 between this SNP and EHR-OSA was primarily observed in individuals who were ≤50 years old 336 (β=-0.24, p=6.10×10 -3 ), rather than those who were older than 50 (β=0.06, p=2.54×10 -1 ). The 337 associations between two SNPs and EHR-OSA were modified by sex (Table S3 ). Tests 338 conducted separately in males versus females indicated that the association between an 339 intronic variant in the fat mass and obesity-associated (FTO) gene (rs8050136; β=-0.14, 340 p=2.91×10 -2 ) and EHR-OSA was primarily observed in males (β=0.09, p=3.02×10 -2 ), rather than 341 females (β=-0.02, p=6.62×10 -1 ). The association between a missense variant in the 342 apolipoprotein E (APOE) gene and EHR-OSA was also influenced by sex (rs429358; β=-0.22, 343 p=1.66×10 -2 ), but was not significantly associated in males or females (Table S3 ). BMI also 344 influenced the association between the rs429358 SNP in APOE with EHR-OSA (β=0.02, 345 p=8.56×10 -3 ), as well as modified the effects of five additional SNPs on EHR-OSA (Table S3) . 346
However, there were no significant associations when stratifying into normal/overweight and 347 obese participants (Table S3) . 348
In the VUMC African American dataset, age, sex or BMI modified the associations 349 between three SNPs and EHR-OSA (Table S3 ). Two SNPs were differentially associated with 350 EHR-OSA in covariate-defined subgroups ( Figure S2 , Table S3 ). In particular, age modified the 351 association between an intronic variant in the kinetochore associated 1 (KNTC1) gene and 352 EHR-OSA (rs10734924; β=0.02, p=2.16×10 -2 ), but no differences were observed when 353 stratifying by age (Table S3 ). Sex modified the association between a variant located ~2kb 354 upstream of the ZFP36 ring finger protein (ZFP36) gene and EHR-OSA (rs251864; β=-0.45, 355 p=2.74×10 -2 ); this association was observed primarily in females (β=-0.33, p=6.44×10 -3 ) but not 356 in males (β=0.19, p=1.89×10 -1 ). BMI influenced the association between an intronic variant in 357
the TraB domain containing 2B (TRABD2B) gene and EHR-OSA (β=-0.03, p=2.20×10 -2 ), with 358 the association observed primarily in individuals with BMI>30 (β=-0.25, p=5.40×10 -2 ), rather 359 than with BMI≤30 (β=0.15, p=4.75x10 -1 ). 360 361
Associations of OSA candidate variants with sleep study report traits 362
There were 21 OSA candidate SNPs that were associated with at least one quantitative 363 measure of OSA severity obtained from sleep study reports at Geisinger (Figure 2 , Tables 2 &  364   S4 ). Of these, one SNP was the GABBR1 rs29230 variant which was associated in the meta-365 analysis across all datasets. Two other SNPs were associated with EHR-OSA in the Geisinger 366 dataset, two in the VUMC European American dataset, and 16 SNPs had no significant 367 evidence for associations with EHR-OSA (Table S4) . Notably, the G allele at the GABBR1 SNP 368 rs29230 was associated with both increased risk for EHR-OSA when results from analyses 369 across all three datasets were meta-analyzed, and increased wake after sleep onset in the 370 subset of the Geisinger dataset with available sleep study reports (β=0.08, p=1.73×10 -3 ). In 371 addition, the two missense variants in the LEPR gene that were associated with EHR-OSA were 372 also associated with the mean duration of the respiratory event (rs1137100, β=-0.08, 373 p=2.23×10 -2 ; rs1137101, β=-0.07, p=3.01×10 -2 , respectively). Futhermore, presence of the A 374 allele at the rs1137101 SNP, which was associated with reduced risk for EHR-OSA, was also 375 associated with a decreased number of awakenings (β=-0.05, p=9.40×10 -3 ) and an increased 376 percentage of sleep efficiency (β=0.06, p=2.28×10 -3 ). Notably, the intronic FTO variant which 377 was associated with increased risk for EHR-OSA solely in males with European ancestry from 378 the VUMC dataset was also associated with a longer mean duration of the respiratory event in 379 the entire Geisinger dataset (rs8050136, β=0.09, p=8.08×10 -3 ). There was also a missense 380 variant in ADRB2 that was associated with reduced risk for EHR-OSA in European Americans 381 from the VUMC dataset but an increased Central Apnea Index in the Geisinger dataset 382 (rs1042713, β=0.04, p=3.74×10 -2 ). While not significant, the beta calculated for this SNP in the 383
Geisinger dataset indicated a positive direction of effect for EHR-OSA (β=0.01, p=8.18×10 -1 ). 384
As mentioned above, there were also 16 SNPs that were associated with quantitative 385 sleep study report variables with no evidence for an association with EHR-OSA ( Figure 2 , Table  386 S4). These included associations between a SNP in a non-coding transcript of prostaglandin E 387 receptor 3 (PTGER3) and two respiratory indices, as well as three measures of sleep efficiency 388 (rs1409986 , Table S4 ). Additional SNPs associated with more than one sleep study report trait 389
included an intronic SNP in the interleukin 6 (IL6) gene, rs1800795, which was associated with 390 sleep efficiency (β=0.05, p=1.23×10 -2 ) as well as wake after sleep onset (β=-0.04, p=2.67×10 -2 ); 391 an intronic variant in the tetraspanin 18 (TSPAN18) gene, rs74472562, with the mean duration 392 of a respiratory disturbance (β=-0.17, p=3.53×10 -2 ) and reports of sleepiness (β=0.14, 393 p=1.61×10 -2 ); an intronic variant, rs7804372, in the caveolin 1 (CAV1) gene with the mean 394 duration of both a respiratory disturbance (β=0.08, p=3.65×10 -2 ) as well as apnea/hypopnea 395 (β=0.06, p=4.37×10 -2 ); and a SNP, rs7412, tagging the ε2 allele in APOE with four different 396 respiratory indices ( Figure 2 , Table S4 ). 397 398
Phenome-wide association studies of OSA candidate variants 399
Seven of the SNPs previously reported in the literature to be associated with OSA were 400 associated (q<5.0×10 -2 ) with other clinical traits derived from the EHR in discovery analyses 401 conducted in the Geisinger dataset (Figure 3 , Tables 2 & S5-S6). Of these, four SNPs that were 402 validated for an association with EHR-OSA in at least one analysis dataset were also 403 associated with traits reflecting immune diseases, peripheral nerve disorders, diabetes and 404 genitourinary symptoms (Figure 3 , Tables 2, S3 & S6) . Specifically, presence of the A allele at 405 the intronic LPAR1 variant, rs7030789, was associated with increased risk for EHR-OSA in the 406
Geisinger dataset, as well as increased risk for evidence of nocturia (β=0.23, p=6.36×10 -6 , 407 q=7.99×10 -3 ; Figure 4a ). The association with nocturia reflected in the PheCode for 'Frequency 408 of urination and polyuria', but not EHR-OSA, generalized in the VUMC African American dataset 409 (β=0.46, p=3.68×10 -2 , q=9.78×10 -1 ). In addition, an association between the rs1800629 variant 410 near TNF-α and celiac disease was observed in the entire Geisinger dataset (β=1.17, 411 p=4.69×10 -23 , q=2.57×10 -19 ); this SNP was primarily associated with EHR-OSA in individuals 412 from Geisinger with BMI≤30 (β=-0.20, p=1.03×10 -2 ). In this particular subgroup defined by lower 413 BMI, the SNP near TNF-α was also associated with diabetes mellitus codes (β=0.09, 414 p=4.09×10 -5 , q=1.47×10 -2 ), and increased measures of blood glucose (β=2.08, p=6.98×10 -5 , 415 q=1.68×10 -2 ), hemoglobin A1c (β=0.06, p=1.67×10 -4 , q=3.01×10 -2 ) and natriuretic peptide B 416 (β=48.20 p=3.96×10 -5 , q=1.47×10 -2 ). The association between the A allele at the rs1800629 417 SNP near TNF-α and evidence of celiac disease replicated in the entire VUMC European 418
American dataset (β=1.03, p=1.30×10 -6 , q=6.11×10 -3 ; Figure 4b ). The same allele at this SNP 419 was also associated with increased risk for EHR-OSA in this dataset (Table 2 ). In addition, an 420
intronic FTO variant (rs8050136), while not associated with EHR-OSA in the entire Geisinger 421 dataset, was associated with OSA severity reflected by a longer duration of respiratory 422 disturbance and with diabetes mellitis (β=0.08, p=2.26×10 -6 , q=3.34×10 -3 ). The association 423 between the intronic FTO SNP and diabetes mellitis replicated in the VUMC European ancestral 424 dataset (β=0.10, p=3.23×10 -3 , q=1.00). Notably, this SNP was associated with EHR-OSA 425 specifically in males with European ancestry from VUMC and was also associated with diabetes 426 mellitis in this same subgroup (β=0.09, p=3.02×10 -2 , q=9.99×10 -1 ). Finally, the NRG1 intronic 427 rs10097555 variant which was only associated with EHR-OSA in the VUMC African American 428 dataset ( Figure 1 , Table 2 ) was instead associated with evidence of peripheral nerve disorders 429 in the Geisinger dataset (β=0.47, p=5.31×10 -6 , q=6.92×10 -3 ); however, the association between 430 this SNP and peripheral nerve disorders did not replicate in the VUMC European American 431 dataset or generalize in the VUMC African American dataset (Table S5) . 432
There were two OSA candidate SNPs that, while not associated with EHR-derived 433 diagnosis of OSA in any of the datasets, were associated with measures of OSA severity 434 defined using variables from sleep study reports (Table S4) , as well as other clinical codes and 435 laboratory values (Table S5 ). This included the SNP tagging the ε2 allele in APOE mentioned 436 above and the ε4 allele tagging SNP (rs429358). Specifically, there were associations between 437 the C allele at rs429358 and reduced time spent with oxygen saturation <89% during rapid-eye 438 movement sleep (β=-0.09, p=2.12×10 -2 ), as well as increased risk for hyperlipidemia (β=0.26, 439 p=1.31×10 -23 , q=7.57×10 -20 ), increased triglycerides (β=8.39, p=2.01×10 -15 , q=6.99×10 -12 ), lower 440 levels of HDL cholesterol (β=-1.51, p=1.73×10 -22 , q=8.80×10 -19 ), and increased risk for coronary 441 atherosclerosis (β=0.15, p=1.01×10 -5 , q=1.15×10 -2 ). The associations between rs429358 in 442 APOE with hyperlipidemia (β=0.16, p=1.06×10 -4 , q=2.28×10 -1 ), and lower levels of HDL 443 cholesterol (β=-6.12, p=5.94×10 -6 , q=3.15×10 -4 ) replicated in the VUMC European American 444 dataset; an association with hyperlipidemia (β=0.36, p=6.42×10 -4 , q=3.12×10 -1 ) also generalized 445
to VUMC African Americans. The rs7412 SNP was also associated with hyperlipidemia in both 446 independent European American datasets (Table S5) . 447
One OSA candidate SNP, rs2187668, an intronic variant in the major histocompatibility 448 complex, class II, DQ alpha 1 (HLA-DQA1) gene, had no evidence for an association with EHR-449 OSA or OSA severity but instead with codes for celiac disease in the Geisinger dataset (β=1.62, 450 p=4.46×10 -42 , q=5.80×10 -38 ), which replicated in the VUMC European American dataset 451 (β=1.44, p=6.19×10 -12 , q=1.46×10 -7 ). Additional associations between the HLA-DQA1 SNP and 452 autoimmune diseases of the thyroid (chronic thyroiditis: β=0.53, p=7.33×10 -6 , q=8.88×10 -3 ; 453 hypothyroidism: β=0.15, p=4.64×10 -7 , q=7.67×10 -4 ) replicated in the VUMC European American 454 dataset (chronic thyroiditis: β=0.51, p=1.17×10 -2 , q=1.00; hypothyroidism: β=0.19, p=1.31×10 -4 , 455 q=2.37×10 -1 ). While not replicated, rs2187668 was also associated with measures of calcium, 456 glucose and hemoglobin A1c in the Geisinger dataset (Table S5) . heart failure, and peripheral nerve disorders. SNPs which did not validate for an association with 472 EHR-OSA were instead associated with celiac disease and autoimmune thyroid diseases. We 473 expect that these results will help to tease apart the substantial heterogeneity underlying 474 expression of OSA and provide the basis for more targeted, personalized treatment of OSA that 475 can be tailored to particular symptom or comorbidity profiles. 476
477
EHR-derived evidence supports influences of genetic variation in GABBR1 and LEPR on 478 risk for OSA and OSA severity in United States clinical populations 479
Notably, the G allele at the rs29230 variant located in the GABBR1 gene was associated 480 with increased risk for EHR-OSA when results from analyses conducted separately in the 481 Geisinger, VUMC European Americans and VUMC African Americans were meta-analyzed. 482
This allele was also associated with longer wake after sleep onset in the subset of the Geisinger 483 dataset with available sleep study reports. The association of the rs29230 variant and OSA was 484 originally reported in a candidate gene study conducted in a relatively small population (n=174) 485 of individuals from Turkey 61 . OSA was defined based on an AHI≥5 and controls were confirmed 486 using medical histories. Notably, this study excluded individuals with evidence of an underlying 487 metabolic disorder or chronic obstructive pulmonary disease. The authors observed an effect 488 primarily in men indicating the C allele at rs29230 (reported in the literature on the alternative 489 strand) was increased in OSA patients 61 . A subsequent candidate gene study conducted in 266 490 individuals from China confirmed an association between the C allele at rs29230 and risk for 491 OSA defined as AHI≥5 in patients with no evidence of underlying confounding comorbid 492 conditions, while additionally controlling for differences in BMI between cases and controls 62 . 493
The GABBR1 gene encodes a receptor for the main inhibitory neurotransmitter in humans, 494 gamma-aminobutyric acid (GABA). GABA(B) receptors are expressed in hypoglossal 495 motorneurons innervating the tongue, which are important for inhibiting tongue movement 62 . It is 496 possible that variation in GABBR1 influences risk for OSA by affecting activity of the encoded 497 receptor resulting in dysfunction of the hypoglossal motoneurons 61; 62 . Notably, the functional 498 consequences of the rs29230 missense variant on GABBR1, depending on the isoform, varies 499 across numerous in silico prediction algorithms and is reported by some software to be possibly 500 damaging and others benign (see Ensembl Variant Effect Predictor for the range of 501 consequences, https://uswest.ensembl.org/index.html). Thus, additional functional 502 characterization of this SNP would be useful to help elucidate its potential role in contributing to 503 the expression of OSA. 504
There were also two missense variants in LEPR that had substantial evidence for a 505 relationship with OSA in individuals with genetically informed European ancestry. Similar to the 506 effects reported in previous studies 63 , the G alleles at the LEPR SNPs, rs1137100 and 507 rs1137101, were associated with reduced risk for EHR-OSA in individuals from Geisinger. The 508 same alleles at these SNPs were associated with shorter respiratory events measured via PSG. 509
In addition, the rs1137101 SNP was associated with a reduced number of awakenings and 510 increased sleep efficiency. These variants were originally evaluated in candidate gene studies 511 as LEPR encodes a receptor for the adipocyte-specific leptin hormone and there is evidence of 512 a relationship between leptin levels and OSA 64; 65 . Leptin has been shown to be an antioxidant 513 molecule that could potentially counteract oxidative stress as a consequence of chronic 514 intermittent hypoxia in OSA. Higher levels of this hormone were observed in OSA patients 515 compared to controls 64 , and the AHI is an independent predictor of the evening/morning leptin 516 ratio, suggesting that OSA might affect leptin diurnal rhythms 65 . Notably, in previously reported 517 meta-analyses, the rs1137101 SNP was associated with reduced risk for OSA in European but 518 not East Asian ancestries, while the rs1137100 SNP was evaluated solely in East Asian 519 populations with no conclusive evidence for an association with OSA 63 . In particular, the original 520 study reporting the European ancestral association between rs1137101 and OSA was 521 conducted in a population from Poland with PSG-confirmed cases and controls matched for 522 age, gender and BMI 66 . Given the strong relationship between OSA and obesity, it is interesting 523 to note that these LEPR SNPs are reported in more than one study to be unassociated with risk 524 for obesity 67-69 , suggesting variation in the LEPR gene may have effects on expression of OSA 525 that are independent of obesity. It is unclear what are the functional consequences of these two 526 missense mutations in LEPR; however, both are reported in ClinVar as benign 527 (https://www.ncbi.nlm.nih.gov/clinvar/). 528 529
Many OSA candidate SNPs associate with severity, not diagnosis 530
Of the 21 SNPs that were associated with respiratory indices and measures of sleep 531 quality in the Geisinger dataset, there were 16 that were not associated with an EHR-derived 532 definition of OSA in any analysis dataset or covariate subgroup. It is possible that these 533 associations did not validate for a relationship with EHR-OSA because these SNPs have effects 534 on OSA-related severity measures which are more robust than effects on expression of an 535
EHR-derived OSA diagnosis, which relies on meeting International Classification of Sleep 536
Disorders diagnostic criteria. Notably, one SNP validated specifically for an association with 537 OSA severity similar to what was reported in the literature. The T allele at the intronic TSPAN18 538 SNP, rs74472562, was associated with a shorter duration of the respiratory event in individuals 539
with Latin American ancestry 70 , similar to what was observed in European Americans in our 540 study. We also observed an association between this SNP and increased reports of sleepiness 541 measured with the Epworth Sleepiness Scale. It is possible these results reflect a decreased 542 arousal threshold and individuals with this variant are more likely to wake-up during an event 543 which would explain why event durations are shorter and symptoms of sleepiness are 544 increased. 545
Varying definitions of PSG-based OSA diagnoses within the reviewed literature could 546 also reflect the associations with OSA severity, but not OSA diagnosis that we observed. For 547 example, some studies defined OSA cases as having AHI≥5 71-73 , while others used AHI≥10 74 , 548 AHI≥15 41; 44; 75 , or even presented varying definitions depending on the analysis 76 . Additionally, 549 two reviewed studies were meta-analyses, with varying definitions of OSA depending on the 550 selected study 77; 78 . Many previous studies reporting associations between the candidate SNPs 551 we tested and OSA, compared cases to controls who were defined by these PSG-measured 552 AHI cut-offs, but did not assess potential genetic effects on quantitative measures of OSA 553 severity. It is also possible that even though our definition of EHR-OSA was validated with an 554 excellent NPV, a proportion of EHR-defined non-cases have undiagnosed disease (see 555 Limitations); this bias would be eliminated when relying on OSA severity measures from sleep 556 studies. 557
Overall, the range of associations between OSA candidate SNPs and quantitative 558 measures from sleep study reports highlight the variability of symptoms of patients who come to 559 the clinic to be evaluated for an OSA diagnosis. For example, we observed an association 560 between the reported OSA risk allele 77 at the rs1800765 intronic SNP in IL6 gene and increased 561 sleep efficiency, as well as reduced wake after sleep onset. It is possible that these patients 562 have OSA but, as they are not waking up following an event, are not reporting symptoms and 563 are therefore not being captured in the clinical setting. In addition, the A allele at the rs1409986 564 PTGER3 SNP was associated with the largest number of sleep study report variables, including 565 an increased amount of time spent at low oxygen saturation levels during sleep, but a 566 decreased number of awakenings and increased sleep efficiency. These individuals may have a 567 particularly unfavorable combination of symptoms, as it is possible they have higher arousal 568 thresholds and are therefore less likely to wake up during events. These patients are potentially 569 not recognizing symptoms and as such may not come to the clinic for evaluation. Furthermore, 570 a missense variant in ADRB2 was associated with an increased Central Apnea Index in the 571 Geisinger dataset, but not with EHR-OSA or the AHI. It was, however, associated with reduced 572 risk for OSA diagnosis in the VUMC dataset indicating that the rs1042713 SNP is potentially 573 associated with other forms of sleep disordered breathing. Finally, the APOE ԑ2 tagging SNP 574 was associated with a number of measures of OSA severity and central apnea as well as 575 numerous other comorbidities. These individuals may not be receiving a diagnosis of OSA due 576 to a clinical focus on their other co-occurring conditions. 577 578
Associations of OSA candidate SNPs may not generalize across populations, or may 579 reflect underlying comorbidities 580
There were 19 SNPs (~40% of those tested) reported in the literature to be associated 581 with OSA that did not show an association with either EHR-defined OSA or with measures of 582 OSA severity in our study. Notably, a number of the associations between SNPs tested in our 583 samples of European or African ancestry were identified in individuals representing populations 584 with different ancestral backgrounds (e.g., Latin, East Asian). It is possible that the effects of 585 these variants on OSA do not generalize to populations of European American or African 586
American ancestry. Another potential reason that the associations between these candidate 587
SNPs and EHR-OSA or OSA-related severity measures did not validate is that the original 588 studies did not consider the possibility that the SNP was associated with a prevalent comorbidity 589 in OSA, rather than OSA itself. There was one intronic SNP (rs2187668) in the HLA gene that 590 instead of being associated with EHR-derived evidence for OSA, it was associated with 591 autoimmune diseases of the thyroid and celiac disease, as well as median clinical laboratory 592 values of calcium, glucose and hemoglobin A1c levels in plasma or serum. Studies suggest that 593 hypothyroidism is a risk factor for OSA, with as many as 35% of individuals with these disorders 594 having comorbid, or eventual OSA 79 . Potential mechanisms implicated in the development of 595
OSA as a consequence of autoimmune thyroid diseases include deposition of mucoprotein in 596 the upper airway, reduced neural output to airway musculature, abnormal ventilatory control, 597 and a dual relationship with obesity 80 . In addition, a connection between OSA and celiac 598 disease has been proposed 81 , described in more detail below. While the original study 599 evaluating an association between the HLA variant and OSA excluded a number of important 600 comorbidities that may confound results, there was no mention of excluding individuals with 601 thyroid disorders or celiac disease 82 . As such, it is possible that a proportion of individuals 602 included as cases had underlying autoimmune disorders that were contributing to expression of 603 OSA. This could result in spurious associations in the original study and explain why our study 604 did not observe a relationship between this HLA SNP and evidence of OSA in the EHR. 605 606 OSA candidate variants in LPAR1, FTO, TNF-α,  607 and NRG1 608 A proportion of the candidate variants that were validated for an association with EHR-609 OSA or OSA severity overlap with those associated with risk for co-occurring conditions, 610 suggesting shared etiologies. For example, variation in the LPAR1 gene was associated with 611 EHR-OSA and the frequency of urination, which could reflect an underlying renal disease. 612
Evidence for pleiotropic genetic effects of
Notably, more severe OSA has been shown to contribute to a higher risk of kidney and 613 pancreatic cancer 46 and the encoded receptor is evidenced to play an important role in the 614 development of kidney 83 and pancreatic cancer 84 . Thus, pleiotropic effects of variation in the 615 LPAR1 gene may help to account for the relationship between more severe OSA and comorbid 616 kidney or pancreatic cancer. In addition, a common variant, rs8050136, residing in the locus 617
where FTO is encoded is considered to be one of the most robust obesity-associated loci 34 . A 618 previous PheWAS was conducted to test for associations between rs8050136 and 1,645 ICD-9 619 codes obtained from EHRs available in the electronic Medical Records and Genomics 620 (eMERGE) Network 85 . The rs8050136 variant was associated with codes for sleep apnea 85 . In 621 the independent datasets we evaluated (all eMERGE Network samples were removed), the 622 rs8050136 SNP was associated with EHR-OSA in males with European ancestry from VUMC, 623 with longer durations of respiratory disturbance in the entire Geisinger analysis dataset, and 624 codes for diabetes mellitus in European Americans from Geisinger and VUMC. These results 625 provide evidence for pleiotropic effects influencing expression of obesity, diabetes and OSA in 626 many individuals with European ancestry. 627
We also observed an association between the A allele at the rs1800629 SNP near TNF-628 α and increased risk for EHR-OSA in the VUMC European American dataset, consistent with 629 effects reported in the literature (see Table S2 ). This allele also had a strong effect on the risk 630 for celiac disease in both datasets. These results are also consistent with previously reported 631 associations for celiac disease 86 . A connection between celiac disease and sleep disorders has 632 been proposed 87 . Not surprisingly, symptoms of celiac disease (e.g. gastroesophageal reflux 633 disease) may contribute to disturbed sleep; however, evidence suggests that sleep disorders in 634 individuals with celiac disease are independent of gastrointestinal issues 87 . Furthermore, celiac 635 disease and OSA share common features of lymphatic hyperplasia and local inflammation, and 636 studies conducted in children report an increased prevalence of OSA in patients with celiac 637 disease 81 . Notably, the direction of the effect for the association of the TNF-α SNP with EHR-638
OSA was different in individuals with lower BMIs at Geisinger, with no evidence for a 639 relationship with celiac disease in this subgroup. It is possible that the effects of this variant on 640 expression of both OSA and celiac disease relate to underlying issues with inflammation, 641 mediated by obesity. 642 643
Limitations and Future Directions 644
As mentioned above, a primary limitation of our EHR-based OSA phenotype is the 645 likelihood of undiagnosed OSA among individuals defined as non-cases (e.g., those without 646 OSA-related ICD-9/ICD-10 diagnosis codes). While prior studies among individuals referred for 647 sleep studies suggest that a high percentage may have undiagnosed OSA 88-91 , these studies 648 are typically biased given the increased risk among those already referred for diagnostic testing. 649
In our previous validation study 55 , when calculating the likelihood of OSA based on the 650 symptomless multi-variable prediction score 92 , almost 70% of non-cases had a predicted OSA 651 probability <0.2, while fewer than 3% had a probability of 0.7 or above. Thus, there is strong 652 evidence that a majority of individuals defined in our study as non-cases are true controls. 653
Ultimately, bias introduced by including individuals with undiagnosed OSA in the comparison 654 group of non-cases is expected to make it more difficult to identify significant associations and 655 should not have as strong of an effect on the associations that were validated in this study. 656
Further, we complement analyses testing for associations between candidate SNPs and OSA 657 diagnoses with tests for associations between these SNPs and quantitative OSA severity 658 measures obtained from sleep study reports. This should further account for potential bias 659 related to inaccurate definitions of control status which could make validation more difficult. 660
Regardless, future OSA research using EHR datasets would benefit from studies focused on 661 expanding algorithms to more accurately identify undiagnosed cases of OSA in EHR-derived 662 control samples. 663
Other limitations include the possibility that differing criteria for sleep apnea (hypopneas) 664 at each site influenced results. Specifically, the AHI is the primary measure used to define the 665 diagnostic criteria for OSA. The criteria for what is considered a hypopnea-which is 666
instrumental to the calculation of the overall AHI-has changed within the last decade 93 . As 667 such, use of different scoring criteria for hypopneas results in differential diagnoses of OSA. The 668 possibility that the two clinical sites included in our studies may have adhered to different criteria 669 for hypopnea definitions at various times throughout the duration of the EHR data we analyzed 670 may account for why we observed unique associations between OSA candidate SNPs and 671 EHR-derived OSA when comparing Geisinger to VUMC, particularly with regard to European 672
Americans. However, given that we excluded individuals with only one diagnostic code on 673 different dates at VUMC, and with two codes at Geisinger, we do not expect that this 674 substantially influenced our results. Future work aimed at understanding the proportion of 675 patients who fail to be diagnosed following a sleep study due to differences in hypopnea scoring 676 criteria would be beneficial to alleviating this potential limitation to using EHR-derived datasets. variant, which was also associated with EHR-derived OSA, in the VUMC European American 1101 analysis dataset. Red line denotes FDR-adjusted significance threshold (q<5.0×10 -2 ), blue line 1102 denotes suggestive significance (p<5.0×10 -2 ). 1103 1104 
